[Human recombinant erythropoietin in the treatment of the severe anemia following labor (a preliminary report)].
BUT: The present clinical study was undertaken to evaluate the efficacy, safety and tolerability of r-HuEPO in the treatment of severe anaemia post partum.


METHODS
Five women received Eprex (Cilag), for five days, and iron and folic acid twice daily. Haematological indices were investigated on the 2d, 5th, 14th and 30th day.


RESULTS
On the 30th day the mean haemoglobin concentration was 110 g/l. A rapid haematopoietic effect was shown by an increase in the number of reticulocytes. The peak reticulocytes counts was achieved on the fifth day. The blood pressure at the course of the puerperium was normal. There was no changes in serum electrolytes during treatment with Eprex. The women noted no side effect from rHuEPO.


CONCLUSIONS
The use of rHuEPO may decrease the need for red cell transfusions in severe anaemia postpartum.
Malinova
M
M
D000208:Acute Disease; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D007501:Iron / Q000627:therapeutic use; D007744:Obstetric Labor Complications; D011247:Pregnancy; D011644:Puerperal Disorders / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins; D013997:Time Factors
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D005492:Folic Acid; D007501:Iron